ABRAMS'VCLINICALVDRUGVTHERAPY:VRATIONALESVFORVNURSINGVPRACTICE
,ABRAMS'VCLINICALVDRUGVTHERAPY:VRATIONALESVFORVNURSINGVPRACTICE
,ABRAMS'VCLINICALVDRUGVTHERAPY:VRATIONALESVFORVNURSINGVPRACTICE
, ABRAMS'VCLINICALVDRUGVTHERAPY:VRATIONALESVFORVNURSINGVPRACTICE
Chapter 1, The Foundation of Pharmacology: Quality and Safety
V V V V V V V V
1. AVwomanVdiagnosedVwithVobsessive–
compulsiveVdisorderVhasVbeenVprescribedVoralVparoxetineVhydrochloride.VWhatVisVt
heVexpectedVeffectVforVthisVprescription?
A. CurativeVeffectVonVsymptoms
B. SystemicVeffectVonVsymptoms
C. LocalVeffectVonVsymptoms
D. ParenteralVeffectVonVsymptoms
ANS:V B
Rationale:VDrugsVthatVproduceVsystemicVeffectsVareVtakenVintoVtheVbody,VcirculatedVthrough
VtheVbloodstreamVtoVtheirVsitesVofVactionVinVvariousVbodyVtissues,VandVeventuallyVeliminated
VfromVtheVbody.VCurativeVagentsVareVgivenVtoVcureVaVdiseaseVprocess.VInVthisVcase,Vparoxeti
neVhydrochlorideVwillVcontrolVtheVsymptomsVbutVnotVcureVtheVdisorder.VDrugsVwithVlocalVef
fects,VsuchVasVsunscreenVandVlocalVanesthetics,VactVmainlyVatVtheVsiteVofVapplication.VParoxet
ineVhydrochlorideVisVnotVadministeredVparenterally.VParenteralVagentsVareVadministeredVsub
cutaneously,Vintramuscularly,VorVintravenously.
PTS: 1 REF: p.V3,VIntroduction OBJ: 1
NAT:V ClientVNeeds:VPhysiologicalVIntegrity:VPharmacologicalVandVParenteralVTherapie
sVTOP: Chapter:V1:VTheVFoundationVofVPharmacology:VQualityVandVSafety
KEY:V IntegratedVProcess:VNursingVProcess
BLM:V CognitiveVLevel:VUnderstand NOT:V MultipleVChoice
2. AVclientVhasVbeenVprescribedVanVantibiotic.VThisVmedicationVisVaVnaturallyVoccurring
substanceVthatVhasVbeenVcheG
mRicA
alDlyEm
SoBdOifOieSd.TWhaOtVM
.C isVanotherVnameVforVthisVtypeVofVm
edication?
A. SyntheticVdrug
B. SemisyntheticVdrug
C. BiotechnologyVdrug
D. PrototypeVdrug
ANS:V B
Rationale:VSemisyntheticVdrugsV(e.g.,VmanyVantibiotics)VareVnaturallyVoccurringVsubstancesVt
hatVhaveVbeenVchemicallyVmodified.VSyntheticVdrugsVareVmoreVstandardizedVinVtheirVchemica
lVcharacteristics,VmoreVconsistentVinVtheirVeffects,VandVlessVlikelyVtoVproduceVallergicVreaction
s.VBiotechnologyVdrugsVinvolveVmanipulatingVDNAVandVRNAVandVrecombiningVgenesVintoV
hybridVmoleculesVthatVcanVbeVinsertedVintoVlivingVorganisms.VPrototypeVdrugsVareVtheVfirstVd
rugVofVaVparticularVgroupVtoVbeVdeveloped.
PTS: 1 REF: p.V3,VDrugVSources OBJ: 1
NAT:V ClientVNeeds:VPhysiologicalVIntegrity:VPharmacologicalVandVParenteralVTherapie
sVTOP: Chapter:V1:VTheVFoundationVofVPharmacology:VQualityVandVSafety
KEY:V IntegratedVProcess:VNursingVProcess
BLM:V CognitiveVLevel:VUnderstand NOT:V MultipleVChoice
3. WhichVclassificationVappliesVtoVmorphine?
A. CentralVnervousVsystemVdepressant
B. CentralVnervousVsystemVstimulant
ABRAMS'VCLINICALVDRUGVTHERAPY:VRATIONALESVFORVNURSINGVPRACTICE
,ABRAMS'VCLINICALVDRUGVTHERAPY:VRATIONALESVFORVNURSINGVPRACTICE
,ABRAMS'VCLINICALVDRUGVTHERAPY:VRATIONALESVFORVNURSINGVPRACTICE
, ABRAMS'VCLINICALVDRUGVTHERAPY:VRATIONALESVFORVNURSINGVPRACTICE
Chapter 1, The Foundation of Pharmacology: Quality and Safety
V V V V V V V V
1. AVwomanVdiagnosedVwithVobsessive–
compulsiveVdisorderVhasVbeenVprescribedVoralVparoxetineVhydrochloride.VWhatVisVt
heVexpectedVeffectVforVthisVprescription?
A. CurativeVeffectVonVsymptoms
B. SystemicVeffectVonVsymptoms
C. LocalVeffectVonVsymptoms
D. ParenteralVeffectVonVsymptoms
ANS:V B
Rationale:VDrugsVthatVproduceVsystemicVeffectsVareVtakenVintoVtheVbody,VcirculatedVthrough
VtheVbloodstreamVtoVtheirVsitesVofVactionVinVvariousVbodyVtissues,VandVeventuallyVeliminated
VfromVtheVbody.VCurativeVagentsVareVgivenVtoVcureVaVdiseaseVprocess.VInVthisVcase,Vparoxeti
neVhydrochlorideVwillVcontrolVtheVsymptomsVbutVnotVcureVtheVdisorder.VDrugsVwithVlocalVef
fects,VsuchVasVsunscreenVandVlocalVanesthetics,VactVmainlyVatVtheVsiteVofVapplication.VParoxet
ineVhydrochlorideVisVnotVadministeredVparenterally.VParenteralVagentsVareVadministeredVsub
cutaneously,Vintramuscularly,VorVintravenously.
PTS: 1 REF: p.V3,VIntroduction OBJ: 1
NAT:V ClientVNeeds:VPhysiologicalVIntegrity:VPharmacologicalVandVParenteralVTherapie
sVTOP: Chapter:V1:VTheVFoundationVofVPharmacology:VQualityVandVSafety
KEY:V IntegratedVProcess:VNursingVProcess
BLM:V CognitiveVLevel:VUnderstand NOT:V MultipleVChoice
2. AVclientVhasVbeenVprescribedVanVantibiotic.VThisVmedicationVisVaVnaturallyVoccurring
substanceVthatVhasVbeenVcheG
mRicA
alDlyEm
SoBdOifOieSd.TWhaOtVM
.C isVanotherVnameVforVthisVtypeVofVm
edication?
A. SyntheticVdrug
B. SemisyntheticVdrug
C. BiotechnologyVdrug
D. PrototypeVdrug
ANS:V B
Rationale:VSemisyntheticVdrugsV(e.g.,VmanyVantibiotics)VareVnaturallyVoccurringVsubstancesVt
hatVhaveVbeenVchemicallyVmodified.VSyntheticVdrugsVareVmoreVstandardizedVinVtheirVchemica
lVcharacteristics,VmoreVconsistentVinVtheirVeffects,VandVlessVlikelyVtoVproduceVallergicVreaction
s.VBiotechnologyVdrugsVinvolveVmanipulatingVDNAVandVRNAVandVrecombiningVgenesVintoV
hybridVmoleculesVthatVcanVbeVinsertedVintoVlivingVorganisms.VPrototypeVdrugsVareVtheVfirstVd
rugVofVaVparticularVgroupVtoVbeVdeveloped.
PTS: 1 REF: p.V3,VDrugVSources OBJ: 1
NAT:V ClientVNeeds:VPhysiologicalVIntegrity:VPharmacologicalVandVParenteralVTherapie
sVTOP: Chapter:V1:VTheVFoundationVofVPharmacology:VQualityVandVSafety
KEY:V IntegratedVProcess:VNursingVProcess
BLM:V CognitiveVLevel:VUnderstand NOT:V MultipleVChoice
3. WhichVclassificationVappliesVtoVmorphine?
A. CentralVnervousVsystemVdepressant
B. CentralVnervousVsystemVstimulant
ABRAMS'VCLINICALVDRUGVTHERAPY:VRATIONALESVFORVNURSINGVPRACTICE
